Literature DB >> 26306059

Microcalcification of Tumor is a Predictor of Response to Neoadjuvant Chemotherapy for Invasive Breast Carcinoma.

Aya Murata1, Naoko Sannomiya1, Naoki Miyamoto1, Naoyuki Ueda1, Akira Kamida1, Yuki Koyanagi1, Haruki Nagira1, Eriko Matsuda1, Yuki Hashimoto1, Kengo Sato1, Yumi Hirooka2, Keiko Hosoya2, Yuzo Takagi2, Yuko Tanaka2, Kunio Araki2, Kiyosuke Ishiguro2, Yasuaki Hirooka1.   

Abstract

BACKGROUND: In recent years, neoadjuvant chemotherapy (NAC) is often performed for patients with unresectable breast carcinoma or without indication of breast conserving therapy. However, it is currently difficult to predict response to NAC with diagnostic imaging of breast carcinoma. In this study, we investigated imaging findings that could serve as a predictor of the response to NAC for patients with invasive breast carcinoma.
METHODS: Twenty-six patients with invasive breast carcinoma who received NAC at the Division of Breast and Endocrine Surgery of Tottori University Hospital between January 2010 and May 2014 were retrospectively investigated. Their imaging findings from mammograms and ultrasonograms were reviewed. The association between findings on mammograms and ultrasonograms captured before NAC and response to treatment after NAC was examined.
RESULTS: Of the 26 patients with invasive breast carcinoma, 19 (73%) responded well to treatment and 7 (27%) did not. Most notably, all 10 patients who had microcalcifications on mammogram responded well to treatment (53% of responders), and all patients who did not respond to treatment had no microcalcifications (P < 0.05). Of these 10 patients, 9 (90%) had microcalcifications of comedo type and one (10%) had non comedo type. As a distribution, 8 of the 10 (80%) had a clustered type of microcalcifications and the remaining 2 (20%) had a segmental type of them.
CONCLUSION: Microcalcifications of tumor observed in mammogram (particularly comedo type) could be a predictor of response to NAC for patients with invasive breast carcinoma.

Entities:  

Keywords:  breast carcinoma; microcalcification; neoadjuvant chemotherapy

Year:  2015        PMID: 26306059      PMCID: PMC4546961     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  15 in total

1.  Mammographic appearance of microcalcifications: can they change after neoadjuvant chemotherapy?

Authors:  Lisa Ellen Esserman; Maria d'Almeida; Darlene Da Costa; Deborah M Gerson; Robert J Poppiti
Journal:  Breast J       Date:  2006 Jan-Feb       Impact factor: 2.431

2.  A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

Authors:  A Makris; T J Powles; S E Ashley; J Chang; T Hickish; V A Tidy; A G Nash; H T Ford
Journal:  Ann Oncol       Date:  1998-11       Impact factor: 32.976

3.  Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.

Authors:  Hans-Bernd Prisack; Christiaan Karreman; Olga Modlich; Werner Audretsch; Mahmoud Danae; Mahadi Rezai; Hans Bojar
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

4.  High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.

Authors:  Carmen Criscitiello; Davide Disalvatore; Michele De Laurentiis; Lucia Gelao; Luca Fumagalli; Marzia Locatelli; Vincenzo Bagnardi; Nicole Rotmensz; Angela Esposito; Ida Minchella; Sabino De Placido; Michele Santangelo; Giuseppe Viale; Aron Goldhirsch; Giuseppe Curigliano
Journal:  Breast       Date:  2013-12-04       Impact factor: 4.380

5.  Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Authors:  Thierry Petit; Marc Wilt; Michel Velten; Jean-François Rodier; Jean-Pierre Fricker; Patrick Dufour; Jean-Pierre Ghnassia
Journal:  Breast Cancer Res Treat       Date:  2010-09-08       Impact factor: 4.872

6.  Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

Authors:  T Petit; M Wilt; M Velten; R Millon; J-F Rodier; C Borel; R Mors; P Haegelé; M Eber; J-P Ghnassia
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy.

Authors:  Anna Weiss; Katherine C Lee; Yajahira Romero; Erin Ward; Yeunjeong Kim; Haydee Ojeda-Fournier; John Einck; Sarah L Blair
Journal:  Ann Surg Oncol       Date:  2014-07-24       Impact factor: 5.344

9.  Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Authors:  S T Brower; S Ahmed; P I Tartter; I Bleiweiss; J B Amberson
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

10.  The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation.

Authors:  Jun-jie Li; Canming Chen; Yajia Gu; Genhong Di; Jiong Wu; Guangyu Liu; ZhiMin Shao
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.